Abstract
Background
Most epithelial ovarian cancers present in advanced stages. Traditional management is maximum cytoreductive effort followed by platinum–taxane-based chemotherapy. We hypothesized that providing all chemotherapy before surgery will increase the R0 cytoreductive rate and improve prognosis.
Methods
Patients with advanced epithelial ovarian carcinoma [International Federation of Gynecology and Obstetrics (FIGO) stages IIIC and IV without parenchymal metastasis] were included in a comparative study. Group A underwent cytoreductive surgery followed by six cycles of chemotherapy, and group B completed six cycles of preoperative systemic therapy followed by cytoreduction. Demographic, clinical, surgical and pathologic variables were recorded and analyzed. Main outcome end points were progression-free survival (PFS) and overall survival (OS). Complete cytoreduction (R0) was defined as absence of macroscopic disease. Kaplan–Meier curves were constructed for survival analysis and univariate and multivariate analysis was performed. Significance was considered at p < 0.05.
Results
One hundred five patients were included: 42 in group A and 63 in group B. Mean patient age was 56 years (range 32–85 years). There were no significant differences between groups regarding demographic, clinical, surgical or pathologic variables. Surgical morbidity was low and not different between groups and there was no surgical mortality. R0 cytoreduction was obtained in 35.5 versus 64.5% in groups A and B, respectively. Median PFS and OS for the entire cohort were 16.17 and 38 months, respectively. Median PFS were 14.71 and 17.52 months for groups A and B, respectively (p = NS), and OS were 33.59 and 56.4 months for groups A and B, respectively (p = 0.08). Factors significantly associated with decreased survival on multivariate analysis were non-R0 resection (p < 0.001), anemia (Hb < 12 g/dL; p = 0.004) and comorbidities (Charlson score > 2; p = 0.007).
Conclusions
In spite of nearly doubling the rate of complete cytoreduction and reduce severe surgical complications, preoperative chemotherapy does not improve long-term outcome in advanced epithelial ovarian carcinoma.
Similar content being viewed by others
References
International Agency for Research on Cancer; World Health Organization; GLOBOCAN 2012. Fact sheets by population. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
Torres-Sánchez LE, Rojas-Martínez R, Escamilla-Núñez C, Vara-Salazar E de, Lazcano-Ponce E. Tendencias en la mortalidad por cáncer en México de 1980 a 2011. Salud Publica Mex. 2014;56:473–91.
Surveillance, Epidemiology, and End Results. SEER Stat Fact Sheets: soft tissue including heart cancer. Statistics at a glance. 2015. https://seer.cancer.gov/faststats/selections.php?series=cancer.
Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.
Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103:1070–6.
Solmaz U, Mat E, Dereli ML, et al. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone? J Buon. 2015;20:847–54.
Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol. 2007;105:211–17.
Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.
Gallardo-Rincón D, CXantú-de León D, Alanís-López P, et al. Third national ovarian consensus. Rev Invest Clin. 2011;63:665–702.
Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med. 2004;351:2544–6.
Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007;104:480–90.
Bacalbasa N, Balescu I, Dima S, et al. Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management. Anticancer Res. 2015;35:2315–20.
Rose P, Nerenstone S, Brady M, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Eng J Med. 2004;351:2489–97.
Goh J, Mohan GR, Ladwa R, Ananda S, Cohen PA, Baron-hay S. Frontline treatment of epithelial ovarian cancer. Asia Pac J Clin Oncol. 2015;11:1–16.
Markauskas A, Mogensen O, dePont Christensen R, Jensen PT. Primary surgery or interval debulking for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2014;24:1420–8.
Inciura A, Simavicius A, Juozaityte E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer. 2006;6:153
Brun JL, Rouzier R, Selle F, Houry S, Uzan S, Daraï E. Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy. BMC Cancer. 2009;9:171.
Taşkın S, Güngör M, Ortaç F, Öztuna D. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer. Arch Gynecol Obstet. 2013;288:1399–403.
Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E. Cytoreductive surgery and hipec in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570–5.
Cascales-Campos PA, Gil J, Feliciangeli E, et al. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol. 2015;22:987–93.
Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19:4052–8.
Disclosure
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Medina-Franco, H., Cortés-González, R., Lambreton-Hinojosa, F. et al. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer. Ann Surg Oncol 24, 1330–1335 (2017). https://doi.org/10.1245/s10434-016-5704-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-016-5704-3